# The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer

> **NCT02262897** · PHASE2 · UNKNOWN · sponsor: **Tongji University** · enrollment: 40 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02262897
- **Lead sponsor:** Tongji University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2015-12
- **Final completion:** 2016-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262897, "The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02262897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*